公开(公告)号：WO2021176268A1

公开(公告)日：2021-09-10

申请号：PCT/IB2020/061877

申请日：2020-12-14

Applicant: INDIAN INSTITUTE OF TECHNOLOGY KANPUR

Inventor： KATTI, Dhirendra S. ,  LOHIYA, Garima ,  SOOD, Vishesh

IPC: A61K9/00 ,  B82Y5/00

Abstract: The present invention relates to a targeted multimodal formulation comprising: mesoporous nanoparticle having a pH responsive coating; and an aptamer(s) conjugated to said mesoporous nanoparticle; the pH responsive coating is optionally carboxylated. The formulation may further comprise an anticancer agent.

公开(公告)号：WO2021171083A1

公开(公告)日：2021-09-02

申请号：PCT/IB2020/061921

申请日：2020-12-15

Applicant: INDIAN INSTITUTE OF TECHNOLOGY KANPUR

Inventor： KATTI, Dhirendra S. ,  LOHIYA, Garima

IPC: A61K31/04 ,  A61K31/16 ,  A61K31/167

Abstract: The present invention presents a therapeutic combination Niclosamide with Doxorubicin for improved treatment of breast cancer. Niclosamide, an FDA approved anti-helminthic drug is repurposed as a Wnt signaling inhibitor for cancer therapy along with doxorubicin which is a first line treatment for breast cancer. The therapeutic combination of Niclosamide and doxorubicin caused synergistically enhanced death of breast cancer cells irrespective of their clinical subtype (viz. HR positive, HER2 positive and triple negative). Since single agent therapy proves to be inefficient in treating cancer and combination therapy is the need of the hour in clinics, such a combination therapy holds great potential to be an effective treatment option for breast cancer.